In previous studies, we identified a subset of breast cancer cell lines and primary breast cancers that exhibit aberrant DNA hypermethylation that results in concurrent epigenetic silencing of multiple methylation-sensitive genes (including CEACAM6, CDH1, CST6, ESR1, GNA11, MUC1, MYB, TFF3 and SCNN1A) secondary to DNA methyltransferase enzyme hyper activity associated with overexpression of DNMT3b (12). This evidence concerns the gene CEACAM6 and breast cancer.